As of Thursday close, NuVasive Inc.’s (NASDAQ:NUVA) stock was down -$0.91, moving down -2.24 percent to $39.75. The average number of shares traded per day over the past five days has been 10,675,120 shares. 3 times new highs have been achieved over the past 5 days, with a $1.63 gain in that time frame. In the last twenty days, the average volume was 3,309,755, while in the previous 50 days, it was 1,638,100.
Since last month, NUVA stock retreated -3.87%. Shares of the company fell to $37.93 on 08/25/23, the lowest level in the past month. A 52-week high of $49.53 was reached on 02/09/23 after having rallying from a 52-week low of $35.17. Since the beginning of this year, NUVA’s stock price has dropped by -3.61% or -$1.49, and marked a new high 12 times. However, the stock has declined by -19.75% since its 52-week high.
Valuation Metrics
Right now, NuVasive Inc. (NUVA) has a P/E ratio of about 95.32. The stock’s beta is 1.04. Besides these, the trailing price-to-sales (P/S) ratio of 1.65, the price-to-book (PB) ratio of 2.33.
Financial Health
In the three months ended June 29, NuVasive Inc.’s quick ratio stood at 0.60, while its current ratio was 1.30, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.50, and the total debt-to-equity ratio was 0.89. On the profitability front, the trailing twelve-month gross margin is 71.70% percent. In the year ended June 29, EBITDA margin amounted to 19.18%, whereas operating margins totaled 5.60%. Based on annual data, NUVA earned $865.43 million in gross profit and brought in $1.2 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.30%. Return on equity (ROE) for the past 12 months was 3.30%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NUVA’s revenue rose 2.31% to $307.71 million during the quarter, while net income inched up to $317.79 million. While analysts expected NuVasive Inc. to report $0.55 quarterly earnings, the actual figure was $0.56 per share, beating the consensus estimate by 1.80%. During the quarter, the company generated $52.48 million in EBITDA. The liabilities of NuVasive Inc. were 1.2 billion at the end of its most recent quarter ended June 29, and its total debt was $907.85 million. The value of shareholders’ equity is $52.45 million.
Technical Picture
This quick technical analysis looks at NuVasive Inc.’s (NUVA) price momentum. With a historical volatility rate of 30.52%, the RSI 9-day stood at 49.86% on 31 August.
With respect to its five-day moving average, the current NuVasive Inc. price is up by +4.28% percent or $1.63. At present, NUVA shares trade -0.63% below its 20-day simple moving average and -5.54% percent below its 100-day simple moving average. However, the stock is currently trading approximately -2.50% below its SMA50 and +0.56% above its SMA200.
Stochastic coefficient K was 66.94% and Stochastic coefficient D was 66.42%, while ATR was 1.30. Given the Stochastic reading of 51.56% for the 14-day period, the RSI (14) reading has been calculated as 48.46%. As of today, the MACD Oscillator reading stands at 0.69, while the 14-day reading stands at 0.76.
Analyst Ratings
NuVasive Inc. downgraded its rating on NuVasive Inc. (NASDAQ: NUVA) to an Equal weight in a note to investors on February 10, 2023. The analysts firm previously had an Overweight rating on the stock.NuVasive Inc. (NUVA) has been rated Hold by analysts. According to 0 brokerage firms, NUVA is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate NuVasive Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $50.00, the current consensus forecast for the stock is $44.00 – $58.00. Based on these forecasts, analysts predict NuVasive Inc. (NUVA) will achieve an average price target of $49.97.
